logo.png
University of Calgary Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients
January 05, 2021 07:50 ET | Arch Biopartners
TORONTO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University of Calgary Cumming School of...
FDA Clearance Granted to WishBone Medical’s Pediatric External Fixation System
October 13, 2020 08:33 ET | WishBone Medical, Inc.
WARSAW, Ind., Oct. 13, 2020 (GLOBE NEWSWIRE) -- WishBone Medical, Inc., a leader in pediatric orthopedic medical devices, today announced it has received U.S. Food and Drug Administration (FDA)...
logo.jpg
ImCheck Achieves Initial Positive Independent Safety Review and Initiates Next Stage of Phase I/IIa EVICTION Trial for ICT01
September 10, 2020 05:46 ET | ImCheck Therapeutics SAS
ImCheck Achieves Initial Positive Independent Safety Reviewand Initiates Next Stage of Phase I/IIa EVICTION Trial for ICT01                        Company Receives FDA Approval for US IND ...
logo.png
Arch Biopartners Closes Non-Brokered Private Placement
June 30, 2020 09:21 ET | Arch Biopartners
TORONTO, June 30, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
logo.png
FDA Grants Arch Biopartners Permission to Proceed with Phase II trial to Evaluate Metablok (LSALT peptide) for the Treatment of COVID-19 patients
June 16, 2020 10:48 ET | Arch Biopartners
International, multi-center, randomized, double-blind, placebo-controlled clinical study targeting the prevention of Acute Respiratory Distress Syndrome (ARDS) and Acute Kidney Injury (AKI) in...
logo.png
Arch Biopartners Announces FDA Acknowledgement of its Investigational New Drug Application for Metablok (LSALT peptide)
June 15, 2020 08:19 ET | Arch Biopartners
International, Multi-center, Randomized, Double-Blind, Placebo-Controlled Clinical study targeting the prevention of Acute Respiratory Distress Syndrome (ARDS) and Acute Kidney Injury (AKI) in...
Multimedia Update: FDA Grants Accelerated Approval for Immunomedics’ Trodelvy in Previously-Treated Metastatic Triple-Negative Breast Cancer
April 23, 2020 08:00 ET | Immunomedics, Inc.
First FDA-approved antibody-drug conjugate that targets the Trop-2 antigen Trodelvy is the first antibody-drug conjugate approved by FDA specifically for the treatment of relapsed or refractory...
chf.jpg
CHF Solutions receives 510(k) clearance for Aquadex SmartFlow™ system in Pediatric Patients Weighing 20kg or More
February 26, 2020 08:00 ET | CHF Solutions, Inc.
EDEN PRAIRIE, Minn., Feb. 26, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS) today announced FDA 510(k) clearance in the U.S. of its next generation Aquadex SmartFlow console for use in adult...
ITGR LOGO (2019-09-25) intgr_ful_r_4cp_hor.png
Integer Announces Expanded Active Implantable Medical Device Capabilities
January 24, 2020 08:30 ET | Integer Holdings Corporation
PLANO, Texas, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (“Integer”) (NYSE: ITGR), a leading medical device outsource manufacturer, today announced it has established implantable...
Breakthrough In-Office Ear Tube Solution From Tusker Medical Receives FDA Approval
December 04, 2019 11:43 ET | Tusker Medical
Tula System Offers ENTs, Patients and Parents an Option Without the Operating Room Menlo Park, CA, Dec. 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Tusker® Medical today announced United...